Shire PLC (LON:SHP)‘s stock had its “overweight” rating restated by analysts at JPMorgan Chase & Co. in a research report issued on Monday.

Several other equities research analysts also recently weighed in on the company. Deutsche Bank AG reissued a “buy” rating and issued a GBX 6,200 ($77.46) price objective on shares of Shire PLC in a report on Monday, November 14th. Goldman Sachs Group Inc. reissued a “conviction-buy” rating and issued a GBX 6,300 ($78.71) price objective on shares of Shire PLC in a report on Friday, November 11th. Credit Suisse Group AG reissued an “outperform” rating and issued a GBX 5,200 ($64.97) price objective on shares of Shire PLC in a report on Friday, November 11th. AlphaValue reissued a “buy” rating and issued a GBX 6,714 ($83.88) price objective on shares of Shire PLC in a report on Monday, November 7th. Finally, Bank of America Corp. reissued a “buy” rating and issued a GBX 6,970 ($87.08) price objective on shares of Shire PLC in a report on Thursday, November 3rd. One analyst has rated the stock with a sell rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of GBX 5,992.27 ($74.87).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) opened at 4799.000000 on Monday. The firm’s market cap is GBX 43.20 billion. The firm’s 50-day moving average is GBX 4,929.36 and its 200 day moving average is GBX 4,716.66. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,562.83.

In related news, insider Dominic Blakemore acquired 133 shares of the firm’s stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average price of GBX 5,010 ($62.59) per share, with a total value of £6,663.30 ($8,324.96).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.